论文部分内容阅读
To observe the effects of Phenobarbital on hyperbilirubinemia in patients with icteric viral?hepatitis.Methods Sixty-two patients with viral icteric hepatitis B were randomly divided into two groups: Phenobarbital group received orally phenobarbital 90rag daily (30mg tid) for 2 to 4 weeks in addition to 60mg before sleep, if itch presented in night, plus liver-protective drugs; control group received only liverprotective drugs.Results Therapeutic efficacy of phenobarbital group was significantly better than that of control group(Hc=4.035, P<0.05) particularly in eliminating serum bilirubin and alleviating itch. Synchronized decrease of serum ALT and bilirubin occurred. No obvious side-effects were observed but rash occurred in one case.Conclusion Phenobarbital is safe and efficacious in treating hyperbilirubinemia.
To observe the effects of Phenobarbital on hyperbilirubinemia in patients with icteric viral? Hepatitis. Methods Sixty-two patients with viral icteric hepatitis B were randomly divided into two groups: Phenobarbital group received orally phenobarbital 90rag daily (30 mg tid) for 2 to 4 weeks in addition to 60mg before sleep, if itch presented at night, plus liver-protective drugs; control group received only liverprotective drugs. Results Therapeutic efficacy of phenobarbital group was significantly better than that of control group (Hc = 4.035, P <0.05) particularly in Synchronized decrease of serum ALT and bilirubin occurred. No obvious side-effects were observed but rash occurred in one case. Confirmation Phenobarbital is safe and efficacious in treating hyperbilirubinemia.